“Human-at-the-Helm": Turning Agentic AI into a Strategic Advantage for Global Regulatory Affairs

Blog

Chirag Patel, Assoc. Principal, Regulatory Science and Strategy, Research & Development Solutions, IQVIA

Rachel Mercado, Principal, AI Consulting, Clinical AI & Technology Innovation, IQVIA

Reid D’Amico, PhD, Principal, Regulatory Science & Study Innovation, Real World Solutions, IQVIA

Nicole Duran, Mgr., Regulatory Science and Strategy, Research & Development Solutions, IQVIA

Raja Shankar, VP, Machine Learning, Research and Development Solutions, IQVIA

Apr 15, 2026

Blogs
“Human-at-the-Helm": Turning Agentic AI into a Strategic Advantage for Global Regulatory Affairs

Across regulatory, our most valuable asset is not data; it is judgment. Yet in 2026, our most experienced regulatory team members reported spending nearly half of their time acting as manual bridges- scanning external feeds, filtering noise, and cross-referencing global updates against internal dossiers. This integration gap has become a burden on innovation that few organizations can afford to ignore.

The sheer volume of global regulatory changes, which now exceed 15,000 annually¹, has outpaced human capacity to monitor through manual means alone. Human expertise has remained central to the process; not because experts are fast, but because their judgment is trusted and essential. However, by requiring experts to manually perform the work of integrating and synthesizing global regulatory changes, we are not strengthening human-in-the-loop oversight; we are consuming it. The result is not just slower submission timelines, but a dilution of the strategic focus regulatory teams are meant to provide.

In 2026, agentic AI is breaking this bottleneck. It is not just enhancing this workflow; it is eliminating the need for experts to act as manual integrators. The promise of agentic AI is not about automating the expert; it is about automating the integration. By shifting from a reactive “Search and Review” model to an autonomous “Notify and Act” architecture, we move beyond workflow digitization and return expert judgement to where it creates the most value. Agentic AI is especially suited to this application because it orchestrates multiple steps while maintaining traceability, accuracy, and intelligence in a way that traditional AI tools do not.

Efficiency as a Competitive Moat

The shift to agentic AI is a financial necessity driven by the rise of niche indications and orphan drugs. As portfolios move toward highly targeted patient populations, the traditional regulatory model, where massive teams focus on a few major markets, is being replaced by a global diversified strategy². To remain profitable in these specialized spaces, companies must achieve global reach without proportional increases in operational complexity. agentic AI delivers this scalability through multiple levers, including:

Pre-IND enablement: Agents reduce the burden by automatically synthesizing historical precedents and safety signals, accelerating the transition from discovery to clinic.
Preventing “Precedent Deviations”: By auditing global findings in real-time, agents identify where a response by one agency may contradict a commitment made elsewhere. Early detection reduces downstream delays and program risks.
Operational Capacity: Senior strategists are currently forced to act as manual bridges for fragmented data, diluting the cognitive capacity required for complex regulatory interpretation³; agents compress these tasks into decision-ready insights.

The “Trusted New Architecture”

This “Human-at-the-Helm” model is only possible if AI is built on a foundation of connected intelligence. As noted in the FDA and EMA’s 2026 Joint Guiding Principles⁴, the transition to AI-assisted drug development requires robust human oversight and high model capacity.

Unlike generic tools that merely summarize texts, an industrialized regulatory agentic AI is hardwired into a live, curated streaming trusted global intelligence and validated internal databases. It doesn't just read a new guidance from the FDA; it understands the context of that guideline relative to your specific program with an expert’s judgement becoming the final authoritative seal.

The Workflow Elevation:

Current state (High Friction): An expert burns time scanning weekly intelligent feeds, generating reports, filtering out irrelevant noise and manually cross-referencing potential impacts against a spreadsheet.
Future State (High Flow): The agent runs the monitor 24/7, filters out the noise, identifies the specific product impact, creates targeted reports and presents a “Decision-Ready” assessment to the expert.

The expert no longer spends time finding the signal. They spend their time deciding what to do with it.

Elevating the Role of Regulatory Professionals

When we trust the AI to handle the groundwork, meaning the triage of health authority letters, the harmonization of local labels, review of global regulations and other meaningful tasks, we liberate vast amount of cognitive capacity.

From Retrieval to Strategy
- Instead of manually researching prior precedents and requirements to inform a new submission, the regulatory manager relies on agentic AI and this shift allows for greater time to focus on strategy.
Proactive Risk Management
- With the noise filtering out, teams can see emerging trends earlier. The role shifts from compliance to strategy, identifying emerging global trends before they become hurdles.

The Trust Prerequisite

This elevation is only possible if the foundation is secure. You cannot build a high- functioning agentic AI on shaky unreliable data. To confidently offload the integration task, the AI must be fueled by verified regulatory intelligence. If the data source is trusted, the automation is safe.

The goal of AI in regulatory is not to replace the regulatory mind. It is to free it. By closing the integration gap, we allow our expert teams to stop managing the process and start managing the strategy. Setting up a future state to deliver safer, faster therapies to the patients who are waiting more efficiently.

In a future post, we will explore how we are leveraging IQVIA.ai to build an agentic AI tool for regulatory intelligence. Powered by deep expertise, Healthcare-grade AI^® and proprietary data, IQVIA.ai is a unified, agentic AI platform for life sciences that uses NVIDIA’s AI infrastructure and LangChain’s agent orchestration platform to embed intelligence directly into clinical, commercial and real-world workflows.

IQVIA Institute (2026). Global Medicine Use Trends 2026
IQVIA White Paper (2025): White Paper Summaries- EMEA Thought Leadership October 2025.
IQVIA Institute (2025). The Human Edge of AI: Why Healthcare’s AI Future Depends on Human Judgement.
FDA and EMA Joint Guiding Principles (January 2026). Joint Guiding Principles for AI in Medicines Development.

Efficiency as a Competitive Moat

The “Trusted New Architecture”

Elevating the Role of Regulatory Professionals

The Trust Prerequisite

You may also be interested in

Related solutions